Effects of Liraglutide on Glycemia, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients

• Status: Completed
• Trial end date: 2022-04-20
• Target enrollment: 0
• Participant gender: All

Summary

The study aims to evaluate the effects of Liraglutide on glycemic control, serum markers of inflammation, markers of endothelial dysfunction and a possible correlation with intra and extra-hospital mortality rates in a group of hospitalized diabetic patients compared to a control group of in-patient diabetic in treatment on insulin Basal-bolus.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Palermo
• Treatments: Insulin Glargine; Liraglutide

Criteria

Inclusion Criteria:

• Diabetes mellitus type 2

• Mild-moderate Hyperglycemia (180-400 mg/dl)

• Acute events (Pneumonia, Acute cardiac Ischemia, Ictus, IVU)

Exclusion Criteria:

• Diabetes mellitus type 1

• Diabetic ketoacidosis

• Hyperosmolar coma

• Severe hypoglycaemia

• Acute Pancreatitis

• Cancer

• use of corticosteroids

• pregnancy

• Chronic kidney disease (< 30 ml/min) or hemodialysis